Abstract: The present invention is a method of treating Tourette's Disorder (TD) using GABA ergic drugs that elevate the amount of stored presynaptic GABA and do not significantly increase GABA tone (a continuous background level of GABA signaling) in the brain. The administration of vigabatrin and/or (1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid hydrochloride salt is expressly contemplated.
Type:
Grant
Filed:
July 25, 2014
Date of Patent:
February 9, 2016
Assignees:
Catalyst Pharmaceutical Partners, Inc., New York University, Feinstein Institute for Medical Research
Inventors:
Steven Miller, Jonathan D. Brodie, Stephen Dewey
Abstract: (1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid also known as CPP-115 or its pharmaceutically acceptable salts can be used to treat addiction and neurological disorders such as epilepsy without side effects such as visual field defects caused by vigabatrin (Sabril).
Type:
Grant
Filed:
February 25, 2011
Date of Patent:
March 3, 2015
Assignees:
Catalyst Pharmaceutical Partners, Brookhaven Science Associates, Northwestern University
Inventors:
Richard B. Silverman, Stephen L. Dewey, Steven Miller
Abstract: (1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid also known as CPP-115 or its pharmaceutically acceptable salts can be used to treat addiction and neurological disorders such as epilepsy without side effects such as visual field defects caused by vigabatrin (Sabril).
© 2025 Justia
